Valuation: Summit Therapeutics Inc.

Market Cap 822.78Cr 1.09TCr 953.44Cr 878.85Cr 1.54TCr 1,02600Cr 1.57TCr 11TCr 4.09TCr 51TCr 4.08TCr 3.99TCr 1,75800Cr P/E 2026 *
-12.5x
P/E 2027 * -12.6x
Enterprise Value 796.61Cr 1.05TCr 923.11Cr 850.9Cr 1.49TCr 99TCr 1.52TCr 10TCr 3.96TCr 49TCr 3.95TCr 3.87TCr 1,70200Cr EV / Sales 2026 *
3,255x
EV / Sales 2027 * 195x
Free-Float
16.86%
Yield 2026 *
-
Yield 2027 * -
1 day-1.20%
1 week+1.89%
Current month-20.13%
1 month-19.53%
3 months-15.50%
6 months-22.77%
Current year-19.90%
1 week 13.88
Extreme 13.88
14.81
1 month 12.55
Extreme 12.5501
16.84
Current year 12.55
Extreme 12.5501
29.23
1 year 12.55
Extreme 12.5501
30.98
3 years 1.52
Extreme 1.52
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 54 25/07/2022
Chief Executive Officer 81 01/04/2020
Director of Finance/CFO 48 02/04/2024
Director TitleAgeSince
Chairman 81 01/02/2020
Director/Board Member 48 01/12/2019
Director/Board Member 54 11/11/2020
Date Insider Type Main position Quantity % Market Cap.
12/06Other

Chief Executive Officer

0 0%
12/06Buy

Chief Executive Officer

38,10,000 0.4909%
12/06Buy

Chief Executive Officer

38,10,000 0.4909%
Change 5-day change 1-year change 3-year change Capi.($)
-1.20%+1.89%-31.99%+432.70% 1.09TCr
-0.36%-1.81%+66.37%+120.85% 5.56TCr
+0.82%+15.05%+79.52%+88.67% 5.22TCr
+1.36%+0.36%-14.52%-14.67% 2.31TCr
-1.04%+7.91%+3.91%+413.05% 2.24TCr
+6.78%+14.77%+37.54%-1.86% 1.73TCr
+0.25%+3.05%+29.73%-32.70% 1.59TCr
+2.89%+5.51%+25.42%+188.41% 1.38TCr
-3.35%+8.96%+134.32%+282.61% 1.35TCr
+4.21%+11.01%+33.13% - 1.24TCr
Average +1.04%+4.49%+36.34%+164.12% 2.37TCr
Weighted average by Cap. +0.79%+4.98%+46.16%+137.16%

Financials

2026 *2027 *
Net sales 24.48L 32.35L 28.36L 26.14L 45.9L 31Cr 46.85L 3.14Cr 1.22Cr 15Cr 1.21Cr 1.19Cr 52Cr 4.2Cr 5.56Cr 4.87Cr 4.49Cr 7.88Cr 524.02Cr 8.05Cr 54Cr 21Cr 258.98Cr 21Cr 20Cr 898.04Cr
Net income -66Cr -87Cr -76Cr -70Cr -123.27Cr -8.2TCr -125.82Cr -843.93Cr -326.56Cr -4.05TCr -326.23Cr -319.1Cr -14TCr -68Cr -90Cr -79Cr -73Cr -127.58Cr -8.48TCr -130.23Cr -873.5Cr -338Cr -4.19TCr -337.65Cr -330.28Cr -15TCr
Net Debt -26Cr -35Cr -30Cr -28Cr -49Cr -3.26TCr -50Cr -335.98Cr -130.01Cr -1.61TCr -129.87Cr -127.04Cr -5.59TCr -1.1Cr -1.46Cr -1.28Cr -1.18Cr -2.07Cr -137.75Cr -2.11Cr -14Cr -5.49Cr -68Cr -5.48Cr -5.36Cr -236.07Cr
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
26/26/26 $14.01 -1.20% 41,83,357
25/26/25 $14.18 -0.49% 48,18,395
24/26/24 $14.25 0.00% 67,69,982
23/26/23 $14.25 -0.21% 59,63,357
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
10.60GBP
Average target price
21.41GBP
Spread / Average Target
+101.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SMMT Stock